Gild cc today, PrEP is a big market... The year

Quote:

---

The year-over-year increase was driven by underlying prescription demand growth of 13% mainly Biktarvy. Biktarvy was a number one prescribed regimen in the U.S. in the quarter. In prevention, they're now approximately 224,000 people taking Truvada for PrEP, an increase of approximately 25% year-over-year of active patients.

Our teams are now in the field with Descovy with its recent approval in PrEP. We initiated efforts to educate health care providers and people at risk for HIV about Descovy immediately following the approval and are really quite pleased with anecdotal feedback from providers.

---

Quote:

---

Thanks, Matthew, for the question. So, yes, only a few weeks in, right? We got the approval early October. But even within a few weeks we're off to a strong start. I think, the team is very excited about it, but more importantly the early feedback from physicians is very positive and we're hearing a lot of enthusiasm from our prescribers.

I do want to explain that the PrEP market is a little bit different than the treatment market and that is that it's much larger in the number of prescribers. So there's over 50,000 prescribers that have actually written at least one script of PrEP with Truvada.

So having said that, more than half of the volume that we're seeing in PrEP is actually very concentrated in a couple of thousand specialists who also prescribe in treatment. So that has been our number one focus and target physicians that we have been calling on over the last couple of weeks, because these are folks that obviously largest volume pool, but also folks that have experienced converting from TDF to TAF and also understand the value of DESCOVY and its clinical profile, specifically around the safety with bone and renal.

---